May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Toward Development of Cell Therapies for Human Retinal Disease: Subretinal Delivery of GFP-Labeled Human Forebrain Progenitor Cells to the Primate Eye
Author Affiliations & Notes
  • M. Neuringer
    Oregon National Primate Research Center & Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
  • S. Wang
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • Y. Zhang
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • T. Hwang
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • T. McFarland
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • A. Brown
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • D. M. Gamm
    Ophthalmology & Waisman Center Stem Cell Research Program, University of Wisconsin, Madison, Wisconsin
  • L. Wright
    Waisman Center Stem Cell Research Program, University of Wisconsin, Madison, Wisconsin
  • R. D. Lund
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • P. J. Francis
    Ophthalmology, Casey Eye Institute, OHSU, Oregon
  • Footnotes
    Commercial Relationships  M. Neuringer, None; S. Wang, None; Y. Zhang, None; T. Hwang, None; T. McFarland, None; A. Brown, None; D.M. Gamm, None; L. Wright, None; R.D. Lund, None; P.J. Francis, None.
  • Footnotes
    Support  Lincy Foundation, The Foundation Fighting Blindness, Wynn Foundation, Walsh Foundation, Hear See Hope Foundation, Research to Prevent Blindness and NIH RR00163
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3872. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Neuringer, S. Wang, Y. Zhang, T. Hwang, T. McFarland, A. Brown, D. M. Gamm, L. Wright, R. D. Lund, P. J. Francis; Toward Development of Cell Therapies for Human Retinal Disease: Subretinal Delivery of GFP-Labeled Human Forebrain Progenitor Cells to the Primate Eye. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3872. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Cell-based therapies for retinal disease have shown efficacy in rodent models of human disease. However, further knowledge is needed to translate these findings to human therapy. Key questions remain regarding dosage, cell distribution, cell survival, ocular safety and the best delivery method. Primate eyes provide the best preclinical model, as they share close structural similarity to the human eye including the presence of a macula. We investigated the distribution and efficacy of GFP-labelled human cortical neural progenitor cells (hNPCctx) grafted into the subretinal space of adult rhesus monkeys. Studies of safety and efficacy of GFP-labelled cells also were carried out in RCS rats, in which native unlabelled hNPCctx were previously shown to rescue vision and retinal structure.

Methods: : Neurospheres of GFP-labelled hNPCctx were dissociated into single cell suspensions and 100 µl containing 6x105 cells was injected into the subretinal space either within or outside the macula. In some cases, cyclosporin immunosupression was started 2 days prior to injection. Multifocal ERGs were performed before and after surgery. After 1-4 weeks, animals were sacrificed and eyes were processed for histology. Subretinal injections of hNPCctx-GFP were also evaluated in RCS rats by optomotor-response acuity and morphology.

Results: : Cell injections were followed by rapid retinal reattachment and no adverse events. Injected cells spread outward to a much broader area than the injection bleb. mfERGs documented intact function within injection sites, and morphology showed excellent preservation of retinal structure and no signs of inflammation or rejection. hNPCctx showing robust GFP expression were distributed in the subretinal space in a single layer, with no sign of cells migrating into the inner retina. In RCS rats, hNPCctx-GFP showed the same efficacy and safety profile as unlabeled hNPCctx .

Conclusions: : hNPCctx -GFP injected subretinally in the rhesus monkey eye showed survival up to 4 weeks with minimal side effects and a good safety profile. This study provides a foundation for future studies of cell-based therapy, including evaluation of other potentially therapeutic cell types and tests of efficacy in monkeys with age-related maculopathy.

Keywords: age-related macular degeneration • transplantation • protective mechanisms 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×